Skip to main content
. 2023 Nov 2;8:169. doi: 10.1038/s41541-023-00766-z

Fig. 6. Experimental design and blood clearance of PEGylated LNP in rats.

Fig. 6

a Schematic illustration of the experimental protocols. Wistar rats were injected intramuscularly with 0.009 (L-LNP group), 0.342 (M-LNP group) or 2.358 (H-LNP group) mg phospholipids/kg DiR-LNP on Day 0 and Day 21, respectively. Rats in the Control group were injected with PBS. Serum samples were collected at the indicated 8 time points (5 min, 30 min, 1 h, 3 h, 6 h, 10 h, 24 h, and 48 h) after each injection of DiR-LNP, followed by determination of LNP-associated fluorescence with Spectramax ID5 fluorescent spectrometry. b LNP-associated fluorescence was presented as “mean ± standard deviation” (n = 3) for each group, with differences among various groups after each injection analyzed using the multiple unpaired t test, with P values adjusted for FDR (false discovery rate). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. c Blood clearance profile of DiR-LNP in rats based on LNP-associated fluorescence obtained at 3 h, 6 h, 10 h, 24 and 48 h, with fitted curves created by Prism 9.2.0 (GraphPad Software). d Blood clearance profile of DiR-LNP in rats based on LNP-associated fluorescence obtained at 5 min, 30 min, and 1 h, with fitted curves created by Prism 9.2.0 (GraphPad Software). As the earliest three time points presented in (d) would become invisible if combined with 5 later time points, blood clearance profile of DiR-LNP based on all 8 time points was presented as two parts (c and d). Data in (c) and (d) were presented as “mean ± standard deviation” (n = 3) for each group, with differences between two injections analyzed using the multiple unpaired t test, with P values adjusted for FDR (false discovery rate). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.